Identification | Back Directory | [Name]
6-chloro-5-(4-(1-hydroxycyclobutyl)phenyl)-1H-indole-3-carboxylicacid | [CAS]
1467057-23-3 | [Synonyms]
CS-2760 EOS-61684 PF 6409577 PF-06409577 PF 06409577;PF06409577 PF-06409577 >=98% (HPLC) PF-06409577;PF 06409577;PF06409577 6-chloro-5-(4-(1-hydroxycyclobutyl)phenyl)-1H-indole-3-carboxylicacid 1H-Indole-3-carboxylic acid, 6-chloro-5-[4-(1-hydroxycyclobutyl)phenyl]- | [Molecular Formula]
C19H16ClNO3 | [MDL Number]
MFCD29917835 | [MOL File]
1467057-23-3.mol | [Molecular Weight]
341.79 |
Chemical Properties | Back Directory | [Boiling point ]
610.9±55.0 °C(Predicted) | [density ]
1.468±0.06 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: soluble | [form ]
powder | [pka]
3.60±0.30(Predicted) | [color ]
white to beige | [InChI]
InChI=1S/C19H16ClNO3/c20-16-9-17-14(15(10-21-17)18(22)23)8-13(16)11-2-4-12(5-3-11)19(24)6-1-7-19/h2-5,8-10,21,24H,1,6-7H2,(H,22,23) | [InChIKey]
FHQXLWCFSUSXBF-UHFFFAOYSA-N | [SMILES]
N1C2=C(C=C(C3=CC=C(C4(O)CCC4)C=C3)C(Cl)=C2)C(C(O)=O)=C1 |
Hazard Information | Back Directory | [Description]
PF-06409577 is an activator of AMP-activated protein kinase (AMPK) heterotrimers (Kd = 9 nM for α1β1γ1).1 In vitro, it selectively activates β1-containing AMPK isoforms (EC50s = 2.18-7.03 nM) over β2-containing isoforms (EC50s = ≥10 μM). PF-06409577 has an EC50 value of 7 nM in an activation/protection TR-FRET assay using α1β1γ1 AMPK. In vivo, PF-06409577 (≥10 mg/kg) increases phosphorylation of AMPK in rat kidney. It decreases urinary albumin levels in a ZSF1 obese rat model of diabetes, metabolic syndrome, and renal disease when administered at a dose of 100 mg/kg. | [Uses]
PF-06409577 has been used to determine its potential as a therapeutic agent for diabetic nephropathy. | [General Description]
PF-06409577 is a 6-chloro-indole derivative obtained from 5-bromo-6-chloro-indole. | [Biochem/physiol Actions]
PF-06409577 preserves retinal pigment epithelium cells from UV radiation by activating AMPK (AMP-activated protein kinase) signaling. This orally bioavailable and possesses pharmacokinetic properties. PF-06409577 blocks de novo lipid and cholesterol synthesis pathways that shows a decrease in hepatic lipids and mRNA expression of markers of hepatic fibrosis. | [Synthesis]
Methyl 6-chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylate (131 g, 368 mmol), methanol (2.20 L), and an aqueous sodium hydroxide solution (90.2 g, 2.21 mol, dissolved in 740 mL of water) were added to a round bottom flask, and the reaction was stirred for 18 hours at 70 °C. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through diatomaceous earth, and the filtrate was concentrated to approximately 30% of the original volume, at which time no precipitate formation was observed. After addition of water (700 mL), the clarified tan solution was washed with methyl tert-butyl ether (MTBE, 3 x 250 mL) and the organic layer was discarded. 38% hydrochloric acid (200 mL) was added dropwise to the stirred aqueous phase (total volume of about 1800 mL) to a pH of about 2-3 at 18-25°C, followed by a one-time addition of ethyl acetate (250 mL). Upon addition of ethyl acetate, solids began to precipitate. Heptane (250 mL) was slowly added to the stirred non-homogeneous mixture via an addition funnel at room temperature and stirring was continued for 4 hours. The solid was collected by filtration, washed sequentially with water and ethyl acetate-heptane mixture (1:1), dried by filtration at room temperature and dried under vacuum at 50 °C to give a light yellow solid. The solid was dissolved in tetrahydrofuran (630 mL) and stirred at 65 °C (internal temperature) for 4 h. Ethyl acetate (630 mL) was then slowly added through a dropping funnel and the resulting slurry was slowly cooled at room temperature overnight. The solid was filtered, washed with a tetrahydrofuran-ethyl acetate mixture (1:1) and dried under vacuum at 50 °C to give 107.0 g of product. The mother liquor was concentrated and the residue was washed with acetone, filtered and dried to give another 12.5 g of product. The resulting solid was dissolved in ethanol (800 mL) containing 0.3 mL of 1M NaOH aqueous solution, and water (800 mL) was slowly added through a dosing funnel at 55-60 °C, and a precipitate began to form after the addition of water. The suspension was stirred at 60 °C for 2 h, followed by stirring at 40 °C for 24 h, and finally for 40 h at room temperature. The solid was filtered, washed with an ethanol-water mixture (1:1) and dried under vacuum at 50 °C to afford 6-chloro-5-(4-(1-hydroxycyclobutyl)phenyl)-1H-indole-3-carboxylic acid as an off-white crystalline solid (72.4 g, 58% yield). The mother liquor was concentrated to about 30% of the original volume, precipitate was precipitated, filtered and dried in vacuum to give another batch of product (14.5 g, 12% yield). The total yield was 70%. Mass spectrum (ES-): m/z 340.3 ([M-H]-). 1H NMR (400 MHz, DMSO-d6) δ: 12.12 (s, 1H), 11.95 (br.s, 1H), 8.09 (d, 1H), 7.96 (s, 1H), 7.65 (s, 1H), 7.58 (d, 2H), 7.42 (d, 2H). 5.53 (s, 1H), 2.48-2.42 (m, 2H), 2.32 (m, 2H), 1.96 (tq, 1H), 1.62-1.79 (m, 1H). | [storage]
Store at -20°C | [References]
[1] Organic Process Research and Development, 2018, vol. 22, # 6, p. 681 - 696 [2] Patent: US2013/267493, 2013, A1. Location in patent: Paragraph 0696; 0703 [3] Journal of Medicinal Chemistry, 2016, vol. 59, # 17, p. 8068 - 8081 [4] Journal of Medicinal Chemistry, 2018, vol. 61, # 6, p. 2372 - 2383 |
|
Company Name: |
Sigma-Aldrich
|
Tel: |
021-61415566 800-8193336 |
Website: |
https://www.sigmaaldrich.cn |
|